Preview

User

Not a user? Register with this site Forgot your password?

Rational Pharmacotherapy in Cardiology

Advanced search

Features of antihypertensive therapy in the Russian population: data from the ESSE-RF3 study

https://doi.org/10.20996/1819-6446-2024-3010

EDN: LXJQOJ

Abstract

Aim. To evaluate the usage of antihypertensive drugs (AHDs) and their combinations in participants aged 35 to74 years with arterial hypertension (AH) in the population-based study ESSE-RF3.

Material and methods. Representative samples of the population aged 35 to 74 years from 15 regions of Russia (n=28731) with a response rate over 70% were examined in the ESSE-RF3 study. Therapy received by 9944 participants with AH (with systolic BP ≥140 mm Hg and/or diastolic BP ≥90 mm Hg, or when the subject was taking AHDs) was analyzed. Information about AHDs intake (brand name of the drug) was recorded by questionnaire and coded according to International Nonproprietary Names by classes. Statistical analysis was performed using the open-source R 4.1 environment. Comparison of discrete indicators between groups was performed using Fisher’s exact test. The significance level for all tested hypotheses was taken as.05. The study was approved by the Ethics Committee of FGBI “NMRC TPM” of the Ministry of Health of the Russian Federation, each participant signed an informed consent.

Results. Among the patients receiving therapy for AH, angiotensin-converting enzyme inhibitors (ACEIs) were used by 38.8% of participants, angiotensin receptor blockers (ARBs) — 31.6%, betablockers (BBs) — 29.0%, сalcium channel blockers (CCBs) — 21.5%, diuretics — 18.6%, 1.1% — outdated AHDs; 8.6% — other groups of drugs. Monotherapy was used by 53.1% of patients, 33.1% of participants received two, and 13.9% received three AHDs. Among participants taking two or more AHDs (including single-pill combinations (SPC)), males most often received the combination of BB+ ACEI and females — BB+ARBs. SPC AHDs were used by 10.3% of those receiving therapy (males: 9.8%, females: 10.6%). Among SPCs, the top three combinations were CCBs + ACEIs (28%), diuretics + ACEIs (27.5%), and diuretics + ARBs (24.4%).

Conclusion. The population study ESSE-RF3, based on the survey of a representative sample of the Russian population aged 35-74 years, showed that more than a half of participants with AH receiving therapy were used the monotherapy, only every tenth of those treated received SPC. The problem of insufficient patients’ literacy was indicated — about 1% of patients received outdated AGPs. In addition, 8.6% of patients used non-AHDs for the treatment of AH. For improving the control of AH treatment, it is necessary to increase the adherence of patients to the prescribed therapy and more strict adherence of doctors to the published guidelines for AH treatment.

About the Authors

Yu. A. Balanova
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation

Yulia A. Balanova

Moscow


S. A. Shalnova
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation

Svetlana A. Shalnova

Moscow


V. A. Kutsenko
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation

Vladimir A. Kutsenko

Moscow


A. E. Imaeva
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation

Asiia E. Imaeva

Moscow


O. E. Ivlev
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation

Oleg E. Ivlev

Moscow


S. E. Evstifeeva
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation

Svetlana E. Evstifeeva

Moscow


A. V. Kapustina
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation

Anna V. Kapustina

Moscow


M. B. Kotova
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation

Marina B. Kotova

Moscow


S. A. Maksimov
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation

Sergey A. Maximov

Moscow


G. A. Muromtseva
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation

Galina A. Muromtseva

Moscow


T. V. Repkina
Regional Center for Public Health and Medical Prevention
Russian Federation

Tatyana V. Repkina

Barnaul


T. O. Gonoshilova
Regional Center for Public Health and Medical Prevention
Russian Federation

Tatyana O. Gonoshilova

Barnaul


A. V. Kudryavtsev
Northern State Medical University
Russian Federation

Alexander V. Kudryavtsev

Arkhangelsk


N. I. Belova
Northern State Medical University
Russian Federation

Natalia I. Belova

Arkhangelsk


L. L. Shagrov
Northern State Medical University
Russian Federation

Leonid L. Shagrov

Arkhangelsk


M. A. Samotrueva
Astrakhan State Medical University
Russian Federation

Marina A. Samotrueva

Astrakhan


A. L. Yasenyavskaya
Astrakhan State Medical University
Russian Federation

Anna L. Yasenyavskaya

Astrakhan


O. A. Bashkina
Astrakhan State Medical University
Russian Federation

Olga A. Bashkina

Astrakhan


S. V. Glukhovskaya
Sverdlovsk Regional Medical College
Russian Federation

Svetlana V. Glukhovskaya

Ekaterinburg


I. A. Levina
Sverdlovsk Regional Medical College
Russian Federation

Irina A. Levina

Ekaterinburg


E. B. Dorzhieva
Boyanov Center for Public Health and Medical Prevention
Russian Federation

Etta B. Dorzhieva

Ulan-Ude


E. Z. Urbanova
Boyanov Center for Public Health and Medical Prevention
Russian Federation

Ekaterina Z Urbanova

Ulan-Ude


N. Yu. Borovkova
Privolzhsky Research Medical University
Russian Federation

Natalia Yu. Borovkova

Nizhny Novgorod


V. K. Kurashin
Privolzhsky Research Medical University
Russian Federation

Vladimir K. Kurashin

Nizhny Novgorod


A. S. Tokareva
Privolzhsky Research Medical University
Russian Federation

Anastasia S. Tokareva

Nizhny Novgorod


Yu. I. Ragino
Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences
Russian Federation

Yulia I. Ragino

Novosibirsk


G. I. Simonova
Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences
Russian Federation

Galina I. Simonova

Novosibirsk


A. D. Khudyakova
Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences
Russian Federation

Alena D. Khudiakova

Novosibirsk


V. N. Nikulin
Orenburg Regional Center for Public Health and Medical Prevention
Russian Federation

Vadim N. Nikulin

Orenburg


O. R. Aslyamov
Orenburg Regional Center for Public Health and Medical Prevention
Russian Federation

Oleg R. Aslyamov

Orenburg


G. V. Khokhlova
Orenburg Regional Center for Public Health and Medical Prevention
Russian Federation

Galina V. Khokhlova

Orenburg


A. V. Solovieva
Tver State Medical University
Russian Federation

Alla V. Solovieva

Tver


A. A. Rodionov
Tver State Medical University
Russian Federation

Andrey A. Rodionov

Tver


O. V. Kryachkova
Tver State Medical University
Russian Federation

Olga V. Kryachkova

Tver


Yu. Yu. Shamurova
South Ural State Medical University
Russian Federation

Yulia Yu. Shamurova

Chelyabinsk


E, V. Mikhailov
South Ural State Medical University
Russian Federation

Evgeny V. Mikhailov

Chelyabinsk


Yu. O. Tarabrina
South Ural State Medical University
Russian Federation

Yulia O. Tarabrina

Chelyabinsk


M. G. Ataev
Dagestan State Medical Academy
Russian Federation

Magomedrasul G. Ataev

Makhachkala


M. O. Radzhabov
Dagestan Federal Research Centre of the Russian Academy of Sciences
Russian Federation

Magomed O. Radzhabov

Makhachkala


Z. M. Gasanova
Dagestan State Medical Academy
Russian Federation

Zulmira M. Gasanova

Makhachkala


M. A. Umetov
Kabardino-Balkarian State University
Russian Federation

Murat A. Umetov

Nalchik


I. A. Hakuasheva
Kabardino-Balkarian State University
Russian Federation

Inara A. Hakuasheva

Nalchik


i. V. Elgarova
Kabardino-Balkarian State University
Russian Federation

Lilia V. Elgarova

Nalchik


E. I. Yamashkina
Ogarev Mordovia State University
Russian Federation

Ekaterina I. Yamashkina

Saransk


L. А. Balykova
Ogarev Mordovia State University
Russian Federation

Larisa A. Balykova

Saransk


A. A. Usanova
Ogarev Mordovia State University
Russian Federation

Anna A. Usanova

Saransk


A. M. Nikitina
Republican Center for Public Health and Medical Prevention
Russian Federation

Alena M. Nikitina

Yakutsk


N. V. Savvina
North-Eastern Federal University
Russian Federation

Nadezhda V. Savvina

Yakutsk


Iu. E. Spiridonova
North-Eastern Federal University
Russian Federation

Iulia E. Spiridonova

Yakutsk


E. A. Naumova
Republican Center for Public Health and Medical Prevention
Russian Federation

Elena A. Naumova

Cheboksary


V. S. Yudin
Center for Strategic Planning and Management of Biomedical Health Risks
Russian Federation

Vladimir S. Yudin

Moscow


A. A. Keskinov
Center for Strategic Planning and Management of Biomedical Health Risks
Russian Federation

Anton A. Keskinov

Moscow


S. M. Yudin
Center for Strategic Planning and Management of Biomedical Health Risks
Russian Federation

Sergey M. Yudin

Moscow


A. V. Kontsevaya
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation

Anna V. Kontsevaya

Moscow


O. M. Drapkina
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation

Oxana M. Drapkina

Moscow


References

1. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants Lancet. 2021;398(10304):957-80. DOI:10.1016/S0140-6736(21)01330-1.

2. Balanova YuA, Kontsevaya AV, Myrzamatova AO, et al. Economic Burden of Hypertension in the Russian Federation. Rational Pharmacotherapy in Cardiology. 2020;16(3):415-23 (In Russ.) DOI:10.20996/1819-6446-2020-05-03.

3. Shalnova SA, Deev AD, Vihireva OV, et al. The prevalence of hypertension in Russia. Awareness, treatment and control. Profilaktika zabolevanij i ukreplenie zdorov’ja. 2001;4(2):3-7 (In Russ.)

4. Balanova YuA, Drapkina OM, Kutsenko VA, et al. Hypertension In the Russian population during the COVID-19 pandemic: sex differences in prevalence, treatment and its effectiveness. Data from the ESSE-RF3 study. Cardiovascular Therapy and Prevention. 2023;22(8S):3785 (In Russ.) DOI:10.15829/1728-8800-2023-3785.

5. Bochkareva EV, Butina EK, Kim IV, et al. Adherence to antihypertensive therapy: A systematic review of Russian prospective studies from 2000 to 2019. Rational Pharmacotherapy in Cardiology. 2020;16(5):770-9 (In Russ.) DOI:10.20996/1819-6446-2020-10-20.

6. Shalnova SA, Deev AD, Balanova YA, et al. Treatment of hypertension in highrisk patients. Monotherapy or combination? Lechasshii Vrach. 2016;(7):17-23 (In Russ.)

7. Boytsov SA, Drapkina OM, Shlyakhto EV, et al. Epidemiology of Cardiovascular Diseases and their Risk Factors in Regions of Russian Federation (ESSE-RF) study. Ten years later. Cardiovascular Therapy and Prevention. 2021;20(5):3007 (In Russ.) DOI:10.15829/1728-8800-2021-3007.

8. Scientific Organizing Committee of the ESSE-RF. Epidemiology of cardiovascular diseases in different regions of Russia (ESSE-RF). The rationale for and design of the study. Profilakticheskaya Meditsina. 2013;16(6):25-34 (In Russ.)

9. Drapkina OM, Shalnova SA, Imaeva AE, et al. Epidemiology of Cardiovascular Diseases in Regions of Russian Federation. Third survey (ESSE-RF-3). Rationale and study design. Cardiovascular Therapy and Prevention. 2022;21(5):3246 (In Russ.) DOI:10.15829/1728-8800-2022-3246.

10. Kobalava ZhD, Konradi AO, Nedogoda SV, et al. Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):3786. (In Russ.) DOI:10.15829/1560-4071-2020-3-3786.

11. Mancia G, Kreutz R, Brunström M, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH). J Hypertens. 2023;41(1):1-198. DOI:10.1097/HJH.0000000000003480.

12. Shalnova SA, Deev AD, Balanova YuA, et al. Trends of arterial hypertension in Russia: is there a progress in prescription of antihypertensive therapies? (results of studies in 1993–2013). Russian Heart Journal. 2015;14(6):389-96 (In Russ.) DOI:10.18087/rhj.2015.6.2145.

13. Boytsov SA, Balanova YuA, Shalnova SA, et al. Arterial hypertension among individuals of 25–64 years old: prevalence, awareness, treatment and control. By the data from ECCD. Cardiovascular Therapy and Prevention. 2014;13(4):4-14 (In Russ.) DOI:10.15829/1728-8800-2014-4-4-14.

14. Balanova YuA, Shalnova S, Imaeva AE, et al. Prevalence, Awareness, Treatment and Control of Hypertension in Russian Federation (Data of Observational ESSE-RF-2 Study). Rational Pharmacotherapy in Cardiology. 2019;15(4):450- 66 (In Russ.) DOI:10.20996/1819-6446-2019-15-4-450-466.

15. Zaman MA, Awais N, Satnarine T, et al. Comparing Triple Combination Drug Therapy and Traditional Monotherapy for Better Survival in Patients With High-Risk Hypertension: A Systematic Review. Cureus. 2023;15(7):e41398. DOI:10.7759/cureus.41398.

16. Lu Y, Van Zandt M, Liu Y, et al. Analysis of Dual Combination Therapies Used in Treatment of Hypertension in a Multinational Cohort. JAMA Netw Open. 2022;5(3):e223877. DOI:10.1001/jamanetworkopen.2022.3877.

17. Lebedev PA, Garanin AA, Paranina EV. Evolution of antihypertensive combined therapy: from depressin of academician A. L. Myasnikov to modern multi-component drugs. Arterial Hypertension. 2021;27(1):73-82 (In Russ.) DOI:10.18705/1607-419X-2021-27-1-73-82.

18. Bryan AS, Moran AE, Mobley CM, et al. Cost-effectiveness analysis of initial treatment with single-pill combination antihypertensive medications. J Hum Hypertens. 2023;37(11):985-92. DOI:10.1038/s41371-023-00811-3.

19. Balanova JA, Shalnova SA, Kutsenko VA, et al. Population aspects of arterial hypertension therapy. Focus on fixed combinations. Arterial Hypertension. 2022;28(5):482-91 (In Russ.) DOI:10.18705/1607-419X-2022-28-5-482-491.

20. Sirenko Yu, Rekovets O. “The impact of statins addind to the fixed combination antihypertensive therapy on the arterial stiffness in patients with moderate and severe hypertension”. Int J Cardiol Cardiovasc Risk Prev. 2023;18:200190. DOI:10.1016/j.ijcrp.2023.200190.

21. Mahfoud F, Kieble M, Enners S? et al. Use of fixed-dose combination antihypertensives in Germany between 2016 and 2020: an example of guideline inertia. Clin Res Cardiol. 2023;112(2):197-202. DOI:10.1007/s00392-022-01993-5

22. Mobley CM, Bryan AS, Moran AE, et al. Fixed-Dose Combination Medication Use Among US Adults With Hypertension: A Missed Opportunity. J Am Heart Assoc. 2023;12(4):e027486. DOI:10.1161/JAHA.122.027486.


Supplementary files

Review

For citations:

Balanova Yu.A., Shalnova S.A., Kutsenko V.A., Imaeva A.E., Ivlev O.E., Evstifeeva S.E., Kapustina A.V., Kotova M.B., Maksimov S.A., Muromtseva G.A., Repkina T.V., Gonoshilova T.O., Kudryavtsev A.V., Belova N.I., Shagrov L.L., Samotrueva M.A., Yasenyavskaya A.L., Bashkina O.A., Glukhovskaya S.V., Levina I.A., Dorzhieva E.B., Urbanova E.Z., Borovkova N.Yu., Kurashin V.K., Tokareva A.S., Ragino Yu.I., Simonova G.I., Khudyakova A.D., Nikulin V.N., Aslyamov O.R., Khokhlova G.V., Solovieva A.V., Rodionov A.A., Kryachkova O.V., Shamurova Yu.Yu., Mikhailov E.V., Tarabrina Yu.O., Ataev M.G., Radzhabov M.O., Gasanova Z.M., Umetov M.A., Hakuasheva I.A., Elgarova i.V., Yamashkina E.I., Balykova L.А., Usanova A.A., Nikitina A.M., Savvina N.V., Spiridonova I.E., Naumova E.A., Yudin V.S., Keskinov A.A., Yudin S.M., Kontsevaya A.V., Drapkina O.M. Features of antihypertensive therapy in the Russian population: data from the ESSE-RF3 study. Rational Pharmacotherapy in Cardiology. 2024;20(1):4-12. (In Russ.) https://doi.org/10.20996/1819-6446-2024-3010. EDN: LXJQOJ

Views: 1040


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)

Moscow 101990, Russia
Petroverigsky per. 10
Tel.: +7 (499) 553 68 10
е-mail: otsec.rfc@mail.ru

Processing of personal data
supported by NEICON (Elpub lab)